SCHEMBL1187697

SCHEMBL1187697

CC(C)(C)OC(=O)N1CCc2cc(NC(=O)NC3CCCCC3)ccc2C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.57
RAB9A P51151 6/20 0.57
ESR2 Q92731 1/20 0.56
EPHX1 P07099 3/20 0.54
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA9 Q16790 1/20 0.53
USP30 Q70CQ3 1/20 0.51
NR1H2 P55055 1/20 0.50
EPHX2 P34913 4/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
TSHR P16473 1/20 0.48
HTT P42858 1/20 0.48
ALOX5 P09917 1/20 0.47
PIK3CA P42336 1/20 0.47
MTOR P42345 1/20 0.47
POLB P06746 1/20 0.47
NAMPT P43490 1/20 0.46
IGF1R P08069 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1188094 0.99 NPC1 (0.58) NPC1RAB9AESR2EPHX1CA12
SCHEMBL1187991 0.85 NPC1 (0.54) NPC1RAB9AESR2EPHX1NR1H2
SCHEMBL4117399 0.85 NPC1 (0.75) NPC1RAB9AEPHX1CA12CA1
SCHEMBL1188104 0.83 ESR2 (0.61) NPC1RAB9AESR2NR1H2PIK3CA
SCHEMBL1188295 0.83 ESR2 (0.63) NPC1RAB9AESR2NR1H2PIK3CA
SCHEMBL1188540 0.82 ESR2 (0.62) NPC1RAB9AESR2NR1H2SMN1; SMN2
SCHEMBL1187860 0.82 ESR2 (0.62) NPC1RAB9AESR2NR1H2SMN1; SMN2
SCHEMBL31174284 0.82 ESR2 (0.67) NPC1RAB9AESR2NR1H2PIK3CA
SCHEMBL31174286 0.82 ESR2 (0.67) NPC1RAB9AESR2NR1H2PIK3CA
SCHEMBL1188437 0.81 ESR2 (0.61) NPC1RAB9AESR2NR1H2PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735425-B2 Tetrahydroisoquinoline derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-05-27 US disclosed
EP-2256105-B1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2013-12-04 EP disclosed
US-20110034481-A1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-02-10 US disclosed
EP-2256105-A1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2010-12-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034481-A1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE DGAT1, DGAT2, DLAT NPC1 269/4885RAB9A 1878/4885ESR2 3292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.